---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-24-000057"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:25:03.130264+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lisata Therapeutics Q3 2024 net loss $4.9M; cash runway into early 2026; multiple trial updates

## Summary
- Net loss of $4.9M in Q3 2024, improved from $5.3M loss in Q3 2023.
- Cash, cash equivalents and marketable securities of $35.9M as of Sep 30, 2024; funds operations into early 2026.
- Phase 2b ASCEND trial (mPDAC) Cohort A interim data expected at ASCO GI in Jan 2025; Cohort B data mid-2025.
- BOLSTER Phase 2a first-line cholangiocarcinoma enrollment complete ahead of plan; topline data mid-2025; second-line cohort added.
- Entered research collaborations for certepetide: endometriosis (Univ. of Cincinnati) and melanoma (Valo Therapeutics).

## SEC filing metadata
- accession: 0000320017-24-000057
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001724000057/0000320017-24-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001724000057/clbs-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-24-000057
- JSON: https://secwatch.observer/filing/0000320017-24-000057.json
- Plain text: https://secwatch.observer/filing/0000320017-24-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.